Akrivia is introducing first-of-its-kind proprietary Oncology Diagnostic products that, by taking a comprehensive tumour biology-based approach, provide prognostic and predictive information in one test.
Our innovative diagnostic tests take a multi-parametric approach, combining Genetic, Transcriptomic, and Immune signals, which has the potential to advance Precision Oncology.
One of our main goals is to put in place the next-generation diagnostic tests based on our unique classification systems to stratify cancer patients into treatment regimes.
Our novel and innovative methodology, developed by Dr Gupta, reflects the intrinsic biology of the disease. This approach to classifying tumours based on specific disease biology would undoubtedly be more clinically relevant and lead the way to novel paradigms for stratified medicine and tailored therapies.
By doing so, we would be able to create a formal treatment structure that works better than the non-structured approaches currently in use. We also aim to develop effective treatment strategies against cancer based on the identified rational biomarkers.
​
With our deep R&D, we have developed 'MMGILTCS Tumour Classification System' a unique tumour biology-based approach that decodes Genomic Complexity associated with the tumour.
MMGILTCS technology, is the backbone of our next-generation diagnostic products that would offer advantages as follows
​
-
Precise Prognosis based on tumour biology
-
Reduce Overtreatment of Cancer Patients
-
Improve the Treatment Outcome by providing diagnostic support to physicians that would help in designing an optimal Cancer Treatment plan that is tailored to each patient... 'a truly personalized approach'
​
Our MMGILTCS technology-based Molecular Diagnostics (MDx) products for Breast cancer, endometrial cancer and prostate cancer are designed to provide deep molecular insights to help physicians, precise details on specific disease biology by considering each patient tumour's unique genomic and immune makeup.
Careful consideration of each tumour’s genomic and immune landscape equips us to predict the accurate prognosis and best clinical and therapeutic approach for these patients. Currently, no tests can predict the treatment response and guide the selection of the most appropriate therapies for individual patients in these cancer types; existing first and second-generation prognostic diagnostic tests available do not provide any biologically relevant information. Also, most of these existing genomic tools for cancer prognostication are often associated with the same tumour characteristics interrogated by the standard clinicopathological parameters, namely, hormonal status or proliferation, thereby failing to capture the full complexity of tumoural heterogeneity. Whereas the ‘single-gene biomarker’-based precision medicine diagnostic tests focuses on specific genetic alterations/mutations without understanding their nuance, context and significance in a tumour’s genomically complex landscape. This is where the Akrivia approach scores over existing techniques.
Key Benefits of Precision Healthcare
As the cost of drug therapy grows, timely diagnosis and correct treatment could help to reduce a major percentage of the national healthcare bill. This will not only result in financial savings but also lead to existing drug-based therapies becoming safer and more effective.
Akrivia’s vision to apply precision treatments for cancer will allow doctors to improve significantly upon present treatment regimes.
3
Image credit: Shutterstock
The Market Potential
Due to advancements in the field of precision medicine and the high success rates the treatment methodology has shown, it is expected that the market for Precision Medicines is only going to expand. In fact, the Precision Medicine market is already a multi-billion-dollar industry and is expected to grow to the tune of over $216.75 billion by 2028.
This makes it one of the fastest-growing markets in the present economy, which has certainly seen an increase in the number of individuals choosing to opt for personalized treatment. Along with that, high incidences of cancer (according to the report of WHO, the global cancer burden has increased to 18.1 million new cases and 9.6 million deaths in 2018), together with technological advancements such as next-generation sequencing, have fuelled interest in this already flourishing field. So much so that the government and policymakers have also come forward to support this industry’s initiatives.
In particular, the cancer biomarker market is projected to reach about USD 28 billion by the end of 2025, driven by rapid growth in genomic analysis and increasing diagnostic applications of biomarkers in oncology.
4
5
References
1. Personalized Medicine Coalition. The personalized medicine Report. Opportunity, challenges, and the future (2017)
2. Sultana J et al. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013, 4:S73-S77.
3. Gary Kurtzman. A Business Model for Diagnostic Startups-A Business Model for a New Generation of Diagnostics Companies. Biotechnol Healthc. 2005, 2:50-55.
4. BIS Research. Global Precision Medicine Market: Focus on Precision Medicine Ecosystem, Applications, 13 Countries Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2028.
5. Kenneth Research. Cancer Biomarkers Market Size, Growth, Opportunity and Forecast to 2025.
6. Drier Y and Domany E. Do Two Machine-Learning Based Prognostic Signatures for Breast Cancer Capture the Same Biological Processes? 2011, 6: e17795.